Work

Supplementary Figure S1 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1. Schematic depiction of SYNB1891.

DOI: 10.1158/1078-0432.23627065

Authors: Jason J. Luke, Sarina A. Piha-Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janku

Language: English

Topic: Bacterial Cancer Therapy

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4383225076

Cites:

Cited by:

Related to: